Resources
-
Mycoplasma In-Process and Lot Release Test: To PCR Or Not To PCR
CMC Summary Paper: CMC Strategy Forum North America Fall 2003
-
Life Cycle Approach to Setting Specifications for Biotechnology-Derived Products
CMC Summary Paper: CMC Strategy Forum North America Winter 2004
-
Defining Your Product Profile and Maintaining Control Over It - Part 1 through 4
CMC Summary Paper: CMC Strategy Forum North America Summer 2004
-
Lot Release and Characterization Testing of Live-Virus-Based Vaccine and Gene Therapy Products - Part 1 and 2
CMC Summary Paper: CMC Strategy Forum North America Winter 2005 - 2
-
Demonstrating Comparability for Well-Characterized Biotechnology Products: Early Phase, Late Phase and Post Approval
CMC Summary Paper: CMC Strategy Forum North America Winter 2005
-
Design and Successful Implementation of a Stability Program for Biotechnology-Derived Products
CMC Summary Paper: CMC Strategy Forum North America Summer 2005
-
Standard Reference Materials for Biopharmaceutical Products: Strategies to Support Product and Method Specifications
CMC Summary Paper: CMC Strategy Forum North America Summer 2006
-
Glycosylation of Therapeutic Proteins: Current Understanding of Structure-Function Relationship
CMC Summary Paper: CMC Strategy Forum North America Winter 2007 - 2
-
Binding Assays and Bioassays: What Are Their Roles in Lot Release and Stability Testing?
CMC Summary Paper: CMC Strategy Forum North America Winter 2007
-
Quality by Design (QbD) for Biopharmaceuticals
CMC Summary Paper: CMC Strategy Forum North America Summer 2007
-
Extractables and Leachables: Challenges and Strategies in Biopharmaceutical Development
CMC Summary Paper: CMC Strategy Forum North America Winter 2008
-
Raw Material Control Strategies for Bioprocesses
CMC Summary Paper: CMC Strategy Forum North America Winter 2009
-
Practical Applications of Quality Risk Management
CMC Summary Paper: CMC Strategy Forum North America Summer 2009
-
The Role of Higher Order Structure in Defining the Quality of Biopharmaceutical Products
CMC Summary Paper: CMC Strategy Forum North America Winter 2010 - 2
-
Analytical Characterization and Regulatory Considerations for Antibody-Drug Conjugates: Uniting Small Molecule and Biologic Drug Perspectives
CMC Summary Paper: CMC Strategy Forum North America Winter 2010
-
QbD for Biologics: Learning's from the Product Development and Realization Case Study (A-Mab) and the FDA OBP Pilot Program
CMC Summary Paper: CMC Strategy Forum North America Summer 2010
-
A Practical Approach to the Analysis and Immunogenic Potential of Aggregates and Particles - Part 1 and 2
CMC Summary Paper: CMC Strategy Forum North America Winter 2011
-
Challenges and Considerations for Multiproduct Facility Design and Control for Biologics
CMC Summary Paper: CMC Strategy Forum North America Summer 2011
-
CMC Summary Paper: Rapid Pharmaceutical Product Development: Getting Off the Critical Path and onto the Right Path
CMC Summary Paper: CMC Strategy Forum North America Winter 2012 - 2
-
Biosimilar Products: Scientific Principles, Challenges, Opportunities
CMC Summary Paper: CMC Strategy Forum North America Winter 2012